Chronic graft versus host disease (cGVHD) incidence and severity are generally found to be greater after peripheral blood stem cell transplantation (SCT) than after bone marrow transplantation, even if few exceptions are reported, 1 and some studies demonstrate a worse outcome due to increased mortality from GVHD, particularly the extensive type. 2 In vivo T-cell depletion with antithymocyte globulin (ATG) is an effective strategy to decrease the incidence of GVHD. The dose and type of polyclonal antibodies are only partially defined because of wide differences in antibody specificities. 3 GVHD prophylaxis with ATGs may include unwanted side effects such as high risk of infection and relapse. 4, 5 The main utilization of ATG has been for the prophylaxis of GVHD in unrelated bone marrow transplants, with clear benefit. 4, 6 We previously showed that low-dose (15 mg/kg, total dose) ATGFresenius (F, Bad Homburg, Germany) was able to decrease the incidence of GVHD after unrelated myeloablative transplants in CML without an increase of relapse. 7 The high anti-CTLA-4 activity present in ATG-F preparation, downregulating the CD28-mediated stimulation of T cells, could partly explain the protective effect on GVHD occurrence. 3 With regard to family donors, instead, ATG-F has been used with bone marrow, 6 while in peripheral blood SCT, it has been almost exclusively associated with reducedintensity conditioning (RIC). 8 No data, however, are available for myeloablative, HLAidentical sibling PBSC transplants. We prospectively planned a prospective phase II study on the use of ATG- Table 1 Patients' characteristics and outcome F for the prophylaxis of GVHD after PBSC sibling transplants in CML. The enrolment was planned to be for 3 years and the trial started in 1999. Here, we report on 12 patients because the accrual has been slower than planned (20 patients), following the widespread use of Glivec as the treatment of CML. 9 Conditioning regimen was oral Busulfan (16 mg/kg), Cyclophosphamide (200 mg/ kg) and ATG-F (15 mg/kg total dose given from day À6 to À2) and GVHD prophylaxis was Cyclosporine A (3 mg/kg) and short-term Methotrexate (15 mg/m 2 on day þ 1, 10 mg/ m 2 on days þ 3, þ 6, þ 11); 66% of patients were in first chronic phase and the median age was 36 years (29-49) and median time from diagnosis to transplant was 14 months (10-37) and two patients received Glivec pre-SCT. No patients experienced grade III-IV aGVHD and the overall cGVHD was 42% (limited 17% and extensive 25%). With a median observation time of 40 months, no relapses (molecular, cytogenetic or haematological) have occurred. There has been no transplant-related mortality. One patient died without cGVHD in complete remission by suicide 30 months after SCT.
ATG-F group No ATG-F group
Our previous experience with myeloablative sibling peripheral blood SCT in CML, treated with the same conditioning regimen and GVHD prophylaxis, except for ATG-F, was characterized by a very high incidence of cGVHD (72%). We have thus compared the findings in the two groups (Table 1) . A marked reduction in the incidence of cGVHD has been observed particularly with regard to the extensive type (48% without ATG-F vs 25% with ATG-F). CMV antigenemia was monitored twice a week for the first 100 days in all patients (with and without ATG-F) and no significant difference of CMV reactivation was observed between the two groups; no CMV disease occurred in both groups.
The dose of ATG-F we used is much lower than the 60 mg/kg, suggested by Schleuning et al 10 as the most effective in a dose finding study. However, that study was about unrelated -not familial -transplants. We reckon, however, that the optimal dose and timing of ATG administration may vary in relation to the underlying disease, the intensity of the preparative regimen, the type of GHVD prophylaxis; such variables may well explain the sometimes conflicting results observed with similar doses, or similar findings with different doses.
Our trial was a phase II study; although in this type of design, a formal comparison between groups (with and without ATG) is not required and the numbers are small, our data suggest that low-dose ATG is effective in preventing cGVHD, without increase in relapse. The results of our study could form the platform for a phase III study.
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